Interalpha trypsin inhibitor biopolymer markers indicative of insulin resistance
    1.
    发明授权
    Interalpha trypsin inhibitor biopolymer markers indicative of insulin resistance 失效
    Interalpha胰蛋白酶抑制剂生物聚合物标志物表明胰岛素抵抗

    公开(公告)号:US07329501B2

    公开(公告)日:2008-02-12

    申请号:US11439587

    申请日:2006-05-23

    IPC分类号: G01N33/53

    CPC分类号: C07K14/8114 Y10T436/24

    摘要: The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.

    摘要翻译: 本发明涉及使用组合的准备步骤与质谱法和飞行时间检测程序的组合,以使特定样品中可验证的生物聚合物的多样性最大化。 然后,在这样一个样本中验证的生物聚合物队列参照其证明至少一种特定疾病状态的能力; 从而使得诊断者能够获得表征所述至少一种疾病状态的存在或不存在的能力,以相对于识别所述生物聚合物的存在和/或不存在,预测疾病风险评估以及开发针对所述疾病的治疗途径。

    Protein biopolymer markers predictive of type II diabetes
    2.
    发明申请
    Protein biopolymer markers predictive of type II diabetes 审中-公开
    预测II型糖尿病的蛋白质生物聚合物标记物

    公开(公告)号:US20070031979A1

    公开(公告)日:2007-02-08

    申请号:US11580470

    申请日:2006-10-12

    IPC分类号: G01N33/50 G01N33/543

    摘要: The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.

    摘要翻译: 本发明涉及使用组合的准备步骤与质谱法和飞行时间检测程序的组合,以使特定样品中可验证的生物聚合物的多样性最大化。 然后,在这样一个样本中验证的生物聚合物队列参照其证明至少一种特定疾病状态的能力; 从而使得诊断者能够获得表征所述至少一种疾病状态的存在或不存在的能力,以相对于识别所述生物聚合物的存在和/或不存在,预测疾病风险评估以及开发针对所述疾病的治疗途径。

    Interalpha trypsin inhibitor biopolymer markers indicative of insulin resistance

    公开(公告)号:US20060211146A1

    公开(公告)日:2006-09-21

    申请号:US11439588

    申请日:2006-05-23

    IPC分类号: G01N33/543

    CPC分类号: C07K14/8114 Y10T436/24

    摘要: The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.

    Fibronectin and fibrinogen biopolymer markers indicative of insulin resistance

    公开(公告)号:US20060211143A1

    公开(公告)日:2006-09-21

    申请号:US11439577

    申请日:2006-05-23

    IPC分类号: G01N33/543

    摘要: The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.

    Complement C3 precursor biopolymer markers predictive of type II diabetes
    6.
    发明授权
    Complement C3 precursor biopolymer markers predictive of type II diabetes 失效
    补充C3前体生物聚合物标志物预测II型糖尿病

    公开(公告)号:US07097989B2

    公开(公告)日:2006-08-29

    申请号:US09993287

    申请日:2001-11-23

    IPC分类号: G01N33/567 A61K38/00

    摘要: The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and/or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.

    摘要翻译: 本发明涉及使用组合的准备步骤与质谱法和飞行时间检测程序的组合,以使特定样品中可验证的生物聚合物的多样性最大化。 然后,在这样一个样本中验证的生物聚合物队列参照其证明至少一种特定疾病状态的能力; 从而使得诊断者能够获得表征与识别生物聚合物的存在和/或不存在相关的至少一种疾病状态的存在或不存在的能力,预测疾病风险评估以及开发针对该疾病的治疗途径。

    Protein biopolymer markers indicative of alzheimer's disease
    7.
    发明授权
    Protein biopolymer markers indicative of alzheimer's disease 失效
    指示阿尔茨海默病的蛋白质生物聚合物标记物

    公开(公告)号:US07074576B2

    公开(公告)日:2006-07-11

    申请号:US09992672

    申请日:2001-11-23

    IPC分类号: G01N33/567 A61K38/00

    摘要: The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and/or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.

    摘要翻译: 本发明涉及使用组合的准备步骤与质谱法和飞行时间检测程序的组合,以使特定样品中可验证的生物聚合物的多样性最大化。 然后,在这样一个样本中验证的生物聚合物队列参照其证明至少一种特定疾病状态的能力; 从而使得诊断者能够获得表征与识别生物聚合物的存在和/或不存在相关的至少一种疾病状态的存在或不存在的能力,预测疾病风险评估以及开发针对该疾病的治疗途径。

    Inter-alpha trypsin inhibitor biopolymer marker indicative of insulin resistance
    8.
    发明申请
    Inter-alpha trypsin inhibitor biopolymer marker indicative of insulin resistance 审中-公开
    表示胰岛素抵抗的α型间胰蛋白酶抑制剂生物聚合物标记物

    公开(公告)号:US20060134699A1

    公开(公告)日:2006-06-22

    申请号:US11351461

    申请日:2006-02-10

    IPC分类号: G01N33/53 G01N33/00

    摘要: The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and/or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.

    摘要翻译: 本发明涉及使用组合的准备步骤与质谱法和飞行时间检测程序的组合,以使特定样品中可验证的生物聚合物的多样性最大化。 然后,在这样一个样本中验证的生物聚合物队列参照其证明至少一种特定疾病状态的能力; 从而使得诊断者能够获得表征与识别生物聚合物的存在和/或不存在相关的至少一种疾病状态的存在或不存在的能力,预测疾病风险评估以及开发针对该疾病的治疗途径。

    Apolipoprotein biopolymer marker indicative of normal human
    9.
    发明申请
    Apolipoprotein biopolymer marker indicative of normal human 失效
    代表正常人的载脂蛋白生物聚合物标记物

    公开(公告)号:US20060084112A1

    公开(公告)日:2006-04-20

    申请号:US09993300

    申请日:2001-11-23

    IPC分类号: G01N33/53

    摘要: The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.

    摘要翻译: 本发明涉及使用组合的准备步骤与质谱法和飞行时间检测程序的组合,以使特定样品中可验证的生物聚合物的多样性最大化。 然后,在这样一个样本中验证的生物聚合物队列参照其证明至少一种特定疾病状态的能力; 从而使得诊断者能够获得表征所述至少一种疾病状态的存在或不存在的能力,以相对于识别所述生物聚合物的存在和/或不存在,预测疾病风险评估以及开发针对所述疾病的治疗途径。

    Biopolymer marker indicative of disease state having a molecular weight of 1518 daltons
    10.
    发明申请
    Biopolymer marker indicative of disease state having a molecular weight of 1518 daltons 失效
    指示分子量为1518道尔顿的疾病状态的生物聚合物标记物

    公开(公告)号:US20050287599A1

    公开(公告)日:2005-12-29

    申请号:US11144402

    申请日:2005-06-03

    CPC分类号: G01N33/6893

    摘要: The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

    摘要翻译: 本发明涉及使用组合的准备步骤与质谱法和飞行时间检测程序的组合,以使特定样品中可验证的生物聚合物的多样性最大化。 然后,在这样一个样本中验证的生物聚合物队列参照其证明至少一种特定疾病状态的能力; 从而使得诊断者能够获得表征所述至少一种疾病状态的存在或不存在与识别所述生物聚合物的存在和/或不存在的能力。